How much funding has Adagene raised?

Adagene has raised $180.0M in total funding, most recently a Corporate Round.

Who are Adagene's investors?

Adagene's investors include F-Prime Capital, Sanofi Ventures, General Atlantic, Sequoia China, Eight Roads Ventures, Fidelity Biosciences.

Where is Adagene headquartered?

Adagene is headquartered in Suzhou, China.

What industry is Adagene in?

Adagene operates in Artificial Intelligence, Biotech, Healthcare, Life Sciences.

Adagene

IPO

Public · Suzhou, China · Founded 2011 · $180.0M raised

Artificial Intelligence

Biotech

Healthcare

Life Sciences

Headquarters: Suzhou
Employees: 51–200
Founded: 2011
Business Model: B2B
Website: adagene.com

Total Funding: $180.0M
Last Round: $25.0M Corporate RoundJul 2025
Rounds: 5
Type: Public

About

Adagene is a Nasdaq-listed, platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based cancer immunotherapies. Powered by its proprietary SAFEbody and NEObody technologies, Adagene designs antibodies with superior safety, tolerability, and efficacy profiles. The company combines computational biology and AI to identify candidates with novel mechanisms of action addressing unmet patient needs.

Summary

Adagene is an Artificial Intelligence company based in Suzhou, China, founded in 2011. It has raised $180.0M in total across 5 rounds, most recently a $25.0M Corporate Round round in Jul 2025. Investors include F-Prime Capital, Sanofi Ventures and General Atlantic.

LinkedIn X (Twitter)